Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44
Cannabis Bioscience International Holdings (CBIH) has been selected to participate in the DEA hearings on marijuana rescheduling. CEO Dante Picazo will present clinical trial data demonstrating cannabis's therapeutic benefits. The company will provide evidence on safety and efficacy of cannabis compounds while highlighting economic opportunities from rescheduling.
According to Grand View Research, the U.S. cannabis market was valued at $33.6 billion in 2023, with projected growth of 12.1% annually from 2024 to 2030. CBIH, with ten patent submissions, focuses on developing treatments for conditions including cancer, epilepsy, neurodegenerative diseases, and osteoarthritis.
Cannabis Bioscience International Holdings (CBIH) è stata selezionata per partecipare alle audizioni della DEA sulla riassegnazione della marijuana. Il CEO Dante Picazo presenterà dati da studi clinici che dimostrano i benefici terapeutici della cannabis. L'azienda fornirà prove sulla sicurezza e l'efficacia dei composti della cannabis, evidenziando anche le opportunità economiche derivanti dalla riassegnazione.
Secondo Grand View Research, il mercato della cannabis negli Stati Uniti era valutato $33,6 miliardi nel 2023, con una crescita prevista del 12,1% annualmente dal 2024 al 2030. CBIH, con dieci domande di brevetto, si concentra sullo sviluppo di trattamenti per patologie come il cancro, l'epilessia, le malattie neurodegenerative e l'osteoartrite.
Cannabis Bioscience International Holdings (CBIH) ha sido seleccionada para participar en las audiencias de la DEA sobre la reprogramación de la marihuana. El CEO Dante Picazo presentará datos de ensayos clínicos que demuestran los beneficios terapéuticos del cannabis. La empresa proporcionará evidencia sobre la seguridad y eficacia de los compuestos de cannabis, al tiempo que destaca las oportunidades económicas que presenta la reprogramación.
Según Grand View Research, el mercado de cannabis en Estados Unidos se valoró en $33.6 mil millones en 2023, con un crecimiento proyectado del 12.1% anual desde 2024 hasta 2030. CBIH, con diez solicitudes de patente, se centra en desarrollar tratamientos para condiciones que incluyen cáncer, epilepsia, enfermedades neurodegenerativas y artrosis.
대마초 생명과학 국제 홀딩스(CBIH)는 마리화나 재조정에 대한 DEA 청문회에 참여하도록 선정되었습니다. CEO 단테 피카조는 대마초의 치료 이점을 입증하는 임상 시험 데이터를 발표할 것입니다. 회사는 대마 성분의 안전성과 효능에 대한 증거를 제공하고, 재조정으로 인한 경제적 기회도 강조할 것입니다.
그랜드 뷰 리서치에 따르면, 2023년 미국 대마초 시장의 가치는 336억 달러였으며, 2024년부터 2030년까지 연평균 12.1% 성장할 것으로 예상됩니다. CBIH는 10개의 특허 출원으로 암, 간질, 신경퇴행성 질병 및 골관절염과 같은 상태에 대한 치료법 개발에 집중하고 있습니다.
Cannabis Bioscience International Holdings (CBIH) a été sélectionnée pour participer aux audiences de la DEA sur la reclassification de la marijuana. Le PDG Dante Picazo présentera des données d'essais cliniques démontrant les bienfaits thérapeutiques du cannabis. L'entreprise fournira des éléments de preuve sur la sécurité et l'efficacité des composés du cannabis tout en soulignant les opportunités économiques liées à cette reclassification.
Selon Grand View Research, le marché du cannabis aux États-Unis était évalué à 33,6 milliards de dollars en 2023, avec une croissance projetée de 12,1% par an entre 2024 et 2030. CBIH, avec dix dépôts de brevets, se concentre sur le développement de traitements pour des conditions telles que le cancer, l'épilepsie, les maladies neurodégénératives et l'arthrose.
Cannabis Bioscience International Holdings (CBIH) wurde ausgewählt, um an den Anhörungen der DEA zur Neuregelung von Marihuana teilzunehmen. CEO Dante Picazo wird klinische Studiendaten präsentieren, die die therapeutischen Vorteile von Cannabis demonstrieren. Das Unternehmen wird Beweise für die Sicherheit und Wirksamkeit von Cannabisverbindungen liefern und gleichzeitig wirtschaftliche Möglichkeiten, die sich aus der Neuregelung ergeben, hervorheben.
Laut Grand View Research wurde der US-Cannabismarkt im Jahr 2023 auf 33,6 Milliarden US-Dollar geschätzt, mit einer prognostizierten jährlichen Wachstumsrate von 12,1% von 2024 bis 2030. CBIH, mit zehn Patentanmeldungen, konzentriert sich auf die Entwicklung von Behandlungen für Erkrankungen wie Krebs, Epilepsie, neurodegenerative Erkrankungen und Osteoarthritis.
- None.
- None.
HOUSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is honored to announce it was selected from a competitive field of numerous companies as one of the few U.S. bioscience cannabis companies invited to participate in the DEA hearings on the rescheduling of marijuana. Represented by CEO, Mr. Dante Picazo, CBIH will present clinical trial data showcasing the therapeutic benefits and potential of Cannabis sativa L., emphasizing the company’s commitment to pioneering innovative treatments. In its presentation, CBIH will provide robust evidence on the safety and efficacy of cannabis compounds in medical science, while highlighting the economic opportunities a rescheduling could unlock for the entire industry.
“This opportunity reaffirms the importance of advancing cannabinoid research and development. The event provides a vital forum where regulatory authorities can engage directly with entrepreneurs, executives, physicians, scientists, patients, and other key industry stakeholders. Such interaction paves the way for a more informed and equitable regulatory framework for the sector,” says Mr. John Jones, Treasurer and Director of CBIH.
From a financial standpoint, Charles Tamburello, Director of CBIH, underscores the importance of these conferences in solidifying the legitimacy of the medical cannabis market, a key factor in boosting investor confidence. According to a report by global market research firm Grand View Research, published in January 2024, the U.S. cannabis market was valued at
In the September 9, 2024, issue of Forbes, President-elect Donald Trump emphasized that rescheduling marijuana would pave the way for supportive legislation. He stated, "As president, we will prioritize research to unlock the medical potential of marijuana as a Schedule III drug and collaborate with Congress to pass practical laws, including safe banking options for state-authorized businesses and upholding states' rights to establish their own marijuana regulations."
"We are deeply honored to participate in this landmark event, where CBIH will present groundbreaking data on cannabinoids’ potential to treat severe conditions such as cancer, epilepsy, neurodegenerative diseases, and osteoarthritis," expressed Rosangel Andrades, Director of Research and Development at CBIH.
This participation underscores CBIH's commitment to continue developing safe, effective treatments and highlights the urgent need to advance research into cannabis’s therapeutic benefits. With ten patents submitted, CBIH is positioning itself as a leader in advocating for equitable regulation that would grant millions access to innovative solutions for improved quality of life. Participation in the DEA hearings marks a significant step toward a future where cannabinoid-based medicine becomes accessible to all.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
FAQ
What is the significance of CBIH's participation in the DEA rescheduling hearing?
What is the projected growth rate of the US cannabis market according to the 2024 Grand View Research report?
What medical conditions is CBIH researching for cannabis-based treatments?
How many patents has CBIH submitted for cannabis-related research?
